I will soon be writing about the possibility of the first-ever direct-acting antiviral drug (DAAD) for respiratory syncytial virus (RSV), courtesy of Enanta Pharmaceuticals, a Massachusetts biotech company spe
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!